INTEGRATED BIOPHARMA INC Annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest in USD from 2011 to 2023
-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.
-
Summary
-
Integrated Biopharma Inc quarterly/annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest history and growth rate from 2011 to 2023.
- Integrated Biopharma Inc Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for the quarter ending March 31, 2024 was $352K, a 665% increase year-over-year.
- Integrated Biopharma Inc Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for the twelve months ending March 31, 2024 was -$63K, a 115% decline year-over-year.
- Integrated Biopharma Inc annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2023 was $100K, a 96.1% decline from 2022.
- Integrated Biopharma Inc annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2022 was $2.6M, a 64.2% decline from 2021.
- Integrated Biopharma Inc annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2021 was $7.25M.
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Trailing 12 Months (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Annual (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, YoY Annual Growth (%)